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Abstract
Background: Vasoplegia is a severe complication which may occur after cardiac surgery, particularly in patients
with heart failure. It is a result of activation of vasodilator pathways, inactivation of vasoconstrictor pathways and
the resistance to vasopressors. However, the precise etiology remains unclear. The aim of the Vasoresponsiveness in
patients with heart failure (VASOR) study is to objectify and characterize the altered vasoresponsiveness in patients
with heart failure, before, during and after heart failure surgery and to identify the etiological factors involved.
Methods: This is a prospective, observational study conducted at Leiden University Medical Center. Patients with
and patients without heart failure undergoing cardiac surgery on cardiopulmonary bypass are enrolled. The study is
divided in two inclusion phases. During phase 1, 18 patients with and 18 patients without heart failure are enrolled.
The vascular reactivity in response to a vasoconstrictor (phenylephrine) and a vasodilator (nitroglycerin) is assessed
in vivo on different timepoints. The response to phenylephrine is assessed on t1 (before induction), t2 (before
induction, after start of cardiotropic drugs and/or vasopressors), t3 (after induction), t4 (15 min after cessation of
cardiopulmonary bypass) and t5 (1 day post-operatively). The response to nitroglycerin is assessed on t1 and t5.
Furthermore, a sample of pre-pericardial fat tissue, containing resistance arteries, is collected intraoperatively. The
ex vivo vascular reactivity is assessed by constructing concentrations response curves to various vasoactive
substances using isolated resistance arteries. Next, expression of signaling proteins and receptors is assessed using
immunohistochemistry and mRNA analysis. Furthermore, the groups are compared with respect to levels of organic
compounds that can influence the cardiovascular system (e.g. copeptin, (nor)epinephrine, ANP, BNP, NTproBNP,
angiotensin II, cortisol, aldosterone, renin and VMA levels). During inclusion phase 2, only the ex vivo vascular
reactivity test is performed in patients with (N = 12) and without heart failure (N = 12).
Discussion: Understanding the difference in vascular responsiveness between patients with and without heart
failure in detail, might yield therapeutic options or development of preventive strategies for vasoplegia, leading to
safer surgical interventions and improvement in outcome.
Trial registration: The Netherlands Trial Register (NTR), NTR5647. Registered 26 January 2016.
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Background
The incidence and prevalence of chronic heart failure is
increasing. Despite the expansion of therapeutic options,
including the development of new pharmacological ther-
apies and cardiological interventions, overall survival
and quality-of-life remains poor [1]. When optimal med-
ical therapy and cardiological interventions have failed
to improve a patient’s condition, surgical intervention
may be a valid option in order to improve cardiac func-
tion. Surgical treatment of end-stage chronic heart
failure encompasses different treatment modalities like
surgical revascularization of ischemic territories using
coronary artery bypass grafting (CABG), alleviating func-
tional mitral valve insufficiency (using restrictive mitral
annuloplasty) and reconstructing left ventricular geom-
etry and thereby improving contractility in patients that
suffered from a large myocardial infarction resulting in a
scarred and dilated left ventricle. Ultimately, left ven-
tricular function can be replaced by performing orthoto-
pic heart transplantation or by implantation of a left
ventricular assist device (LVAD). These surgical options
have improved clinical outcome [2–4]. Unfortunately,
heart failure surgery is associated with an increased risk
on vasoplegia, also named vasodilatory shock [5]. This
syndrome is characterized by hypotension and the con-
tinuous need of vasopressors, despite a normal or high
cardiac index. The incidence of vasoplegia ranges from
11 to 31% in patients undergoing heart failure surgery
[5–9]. The prognosis of vasoplegia is poor. Prolonged
hypotension and the accompanying hypoperfusion lead
to end-organ dysfunction and is associated with an
increased morbidity. An earlier study showed that the
90-day survival rate after heart failure surgery is de-
creased in vasoplegic patients compared with non-
vasoplegic patients (71% vs 91%, P < 0.001) [8].
Vasoplegia is a result of failure of the vascular smooth
muscle cells to constrict to normal endogenous and ex-
ogenous stimuli. Normally, a vascular smooth muscle
cell constricts due to binding of a ligand (e.g. arginine
vasopressin or norepinephrine) to a receptor on the vas-
cular smooth muscle cell surface (Fig. 1). This activates
a signal transduction pathway, resulting in an increase of
the calcium concentration in the cytosol due to release
of intracellular calcium and an influx of extracellular cal-
cium through voltage-gated calcium channels. Binding
of calcium to calmodulin leads to phosphorylation of
myosin light chain kinase, which activates myosin light
chain, leading to vasoconstriction. In contrast, vasodila-
tors (e.g. nitric oxide, atrial natriuretic peptide) increase
cyclic guanosine monophosphate (cGMP) concentra-
tions in the vascular smooth muscle cell. This leads to
the activation of myosin light chain phosphatase, which
deactivates myosin light chain, introducing vasodilata-
tion. The mechanism that causes vasoplegia is thought
Fig. 1 Regulation of vascular smooth muscle tone. Binding of arginine vasopressin and norepinephrine to their receptor on the vascular smooth muscle
cell surface results in an increase of the calcium concentration in the cytosol, thereby activating myosin light chain, leading to vasoconstriction. Vasodilators
(e.g. nitric oxide, atrial natriuretic peptide) deactivate myosin light chain, introducing vasodilatation. AVP, arginine vasopressin; Ca2+, calcium ion, cGMP,
cyclic guanosine monophosphate; MLCK, myosin light chain kinase; MLCP, myosin light chain phosphatase. Adapted from Landry and Oliver [10]
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to be multifactorial. It seems to involve activation of
vasodilator pathways and inactivation of vasoconstrictor
pathways resulting in a resistance to vasopressors, but
the precise etiology remains subject of debate. Vasodila-
tory shock due to sepsis is the most studied etiology, but
it is likely that the pathophysiological mechanisms differ
depending on the underlying etiology. However, Landry
and Oliver [10] propose three mechanisms that contrib-
ute to all types of vasodilatory shock.
1. Activation of adenosine triphosphate (ATP)
dependent potassium channels (KATP) on the
vascular smooth muscle cell.
When the vascular smooth muscle cell depolarizes,
voltage gated calcium channels open, thereby
increasing the calcium concentration in the cytosol,
causing vasoconstriction. In contrast,
hyperpolarization closes the channel, leading to
relaxation. KATP channels influence the membrane
potential (Figs. 2 and 3). Opening leads to an efflux
of potassium, thereby hyperpolarizing the plasma
membrane, causing the voltage gated calcium
channels to close. Under normal circumstances KATP
channels are closed, but they open when intracellular
ATP concentration is low and when lactate and
hydrogen ion concentrations are high, like during
hypoxic and increased metabolic states. Atrial
natriuretic peptide, calcitonin gene-related peptide,
adenosine and increased nitric oxide concentrations
(indirectly) may open the channel as well.
2. Activation of inducible nitric oxide synthase
(iNOS).
iNOS (NOS2), is one of the three isoforms of nitric
oxide synthase. The other forms are neuronal nitric
oxide synthase (nNOS or NOS1) and endothelial
nitric oxide synthase (eNOS or NOS3). The
synthases are responsible for the production of
nitric oxide. Therefore, activation of iNOS leads to
increased vasodilatation (see Fig. 3). Accordingly,
the use of methylene blue, a cGMP inhibitor, seems
to be effective for the treatment of vasoplegic
syndrome [11].
3. Deficiency of arginine vasopressin (AVP).
The binding of AVP to the vascular smooth muscle
cell leads to vasoconstriction. Accordingly, a
deficiency in AVP leads to a reduced ability of the
vascular smooth muscle cell to constrict (see Fig.
3). The role of AVP in vasoplegic shock is
confirmed by Colson et al. [12] who showed that
vasoplegic patients have higher preoperative
Fig. 2 Influence of the KATP channel on the vascular smooth muscle tone. Closing of KATP channels leads to depolarization of the vascular
smooth muscle cell, thereby opening the voltage gated calcium channels and causing vasoconstriction. Opening of the KATP channels leads to an
efflux of potassium, thereby hyperpolarizing the plasma membrane, causing the voltage gated calcium channels to close, which results in
vasodilation. AVP, arginine vasopressin; Ca2+, calcium ion; K+, potassium ion. Adapted from Landry and Oliver [10]
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copeptin (a precursor of AVP) plasma
concentrations, but lower AVP concentration
postoperatively.
Besides these mechanisms, we postulate that other char-
acteristics of heart failure patients make them more prone
to develop vasoplegia. For instance, the chronic endogen-
ous adrenergic (over)stimulation leads to downregulation
and desensitization of myocardial β1-adrenergic receptors
and desensitization β2-adrenergic receptors in heart failure
[13]. This continuous adrenergic stimulation also seems
to result in downregulation and/or desensitization of
vascular α1-adrenoreceptors [14], leading to an altered
responsiveness of the vascular system of heart failure
patients. We hypothesize that the balance of the vascular
system of patients with heart failure is fragile and
therefore could easily be disturbed by the systemic inflam-
matory response (SIRS) reaction caused by the cardiopul-
monary bypass and surgical trauma [15], making these
patients more prone to develop vasoplegia. Furthermore,
the sympathetic activation is likely to be related to the
proinflammatory state of a heart failure patient [16]. In
addition, the medication that is prescribed to heart
failure patients (e.g. beta blockers, ACE inhibitors,
angiotensin receptor blockers, diuretics) influences the
hemodynamics as well and could contribute to the
risk on vasoplegia. Most probably all the above de-
scribed factors may play a role in the development of
vasoplegia after heart failure surgery, but this has
never been proven in patients.
Methods
The Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) checklist is provided in
Additional file 1.
Study design
The aim of the current study is to objectify and
characterize the altered vasoresponsiveness in patients
with heart failure, before, during and after heart fail-
ure surgery and to identify the etiological factors in-
volved. This is a prospective, observational study,
conducted at the Leiden University Medical Center.
Fig. 3 Summary of the three mechanisms contributing to vasodilatory shock: Activation of adenosine triphosphate (ATP) dependent potassium
channels (KATP), activation of inducible nitric oxide synthase (iNOS) and arginine vasopressin (AVP) deficiency. Adapted from Landry and Oliver [10]
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Patients with heart failure will be compared with pa-
tients without heart failure. Figure 4 shows a sche-
matic overview of the study (SPIRIT statement). The
study is divided in two inclusion phases. The protocol
of the patients who are included in phase 1 consists
of several in vivo vascular reactivity tests, an ex vivo
vascular reactivity test and blood and urine sample
analysis. In patients included in phase 2, only the
ex vivo vascular reactivity test is performed.
Participants
Two researchers (MV and MP) screen patients sched-
uled for elective or urgent cardiac surgery on cardiopul-
monary bypass for eligibility. Patients are recruited for
either the heart failure group or the non-heart failure
group. Heart failure is defined according to the Euro-
pean Society of Cardiology guidelines [17]. In order to
be eligible for inclusion in the heart failure group,
patients must meet all of the following inclusion criteria:
1) Diagnosed with heart failure and 2) LVEF ≤35%. Pa-
tients that are included in the non-heart failure group
are 1) not diagnosed with heart failure and 2) have a
LVEF > 50%. In addition, patients are selected according
to the expected cardiopulmonary bypass and estimated
aortic cross clamp duration.
A patients who meets any of the following criteria is
excluded from participation in this study: 1) age < 18
years; 2) incapacitated adults; 3) emergency operation; 4)
patients in need of moderate of high dosages of intra-
venous inotropic support (> 4 gamma dobutamine or
dopamine), vasopressin and/or mechanical support; 5)
patients with aortic valve insufficiency > grade 1; 6) pa-
tients using a daily dosage of nitrates or 7) α-adrenergic
blockers; and 8) patients not willing to sign the consent
form. All included patients receive a subject identifica-
tion code starting at 1001, up to 1060.
Fig. 4 Schedule of enrolment and assessments (SPIRIT statement). * During phase 2, only fat tissue will be harvested and the ex vivo vascular reactivity
test will be performed. t1, before induction; t2, before induction, after start of cardiotropic drugs and/or vasopressors when necessary; t3, after induction;
t4, before the cardiopulmonary bypass is connected; t5, 15min after cessation of cardiopulmonary bypass. Adapted from Landry and Oliver [10]
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Clinical parameters
Baseline characteristics (including age, gender, Euro-
SCORE, comorbidity, medication), perioperative routine
blood values, use of (vasoactive) drugs (e.g. phenylephrine,
norepinephrine, epinephrine, dopamine, dobutamine, mil-
rinone), hemodynamic parameters and transfusion prod-
ucts are registered in the hospital’s electronic patient
information system.
Anesthetics and hemodynamic monitoring
Anesthetics are given according to a standard protocol.
Patients are anesthetized with target-controlled infusion
of propofol and remifentanil or sufentanil. Bispectral
index monitoring is used to guide the anesthetic dosing.
Ketamine and sevoflurane are not used.
Before induction all patients will receive an arterial line
for invasive monitoring of blood pressure and blood sam-
pling. A central venous catheter is inserted in the internal
jugular vein and a flow-directed balloon-tipped pulmonary
artery catheter is introduced after induction. The pressure
transducers of the arterial catheter and central venous
catheter are connected to separate M1006A invasive blood
pressure modules (Hewlett-Packard-medical-products-
group, Andover, MA. USA) for optimal data recording at
a frequency of 100Hz and the resolution 0.2mmHg.
Three different systems are used for hemodynamic mea-
surements. 1) The FloTrac-sensor of the radial artery
catheter is connected to a Vigileo system (Edwards Life-
Sciences, Irvine, CA, USA). The system uses the arterial
pressure waveform and patient characteristics (height,
weight, age and sex) to estimate cardiac output/stroke vol-
ume. The value of central venous pressure was entered
into the Vigileo-monitor in order to calculate systemic
vascular resistance (SVR). 2) The pulmonary artery cath-
eter is connected to a Vigilance-II monitor (Edwards Life-
Sciences, Irvine, CA, USA). The patient characteristics
(height, weight, age) are entered in the monitor and used
for the algorithm. 3) PulseCO™ software (LiDCO, London,
UK) is used for measurement of hemodynamic variables
as arterial blood pressure, cardiac output/stroke volume,
pulse pressure variation, stroke volume variation and after
entering central venous pressure, SVR. The system uses
arterial waveform and patient characteristics (age, height,
weight, and value of hemoglobin). The cardiac output de-
rived from the Vigilance-II monitor, is used to calibrate
the cardiac output as measured by PulseCO. Software of
the LiDCOplus (LiDCOviewSE, LiDCO Ltd., London, UK)
is used for off-line analysis of the vasoreactivity tests. The
decision to evaluate hemodynamic variables with pulse
contour analysis lay in the character of these monitoring
systems. FloTrac/Vigileo and PulseCO, providing a quick
response time to medication induced vaso(motor)reactiv-
ity by beat to beat analysis of arterial blood pressure.
Surgical procedures
Main procedures that are performed are mitral valve
plasty and aorta surgery. In the heart failure group
left ventricular reconstruction and left ventricular as-
sist device implantation are performed as well. All
surgeries are performed via a midline sternotomy with
the use of cardiopulmonary bypass with antegrade
warm blood cardioplegia.
In vivo vascular reactivity test
The vascular reactivity in response to a vasoconstrictor
(phenylephrine, an α1-adrenoreceptor agonist) and vaso-
dilator (nitroglycerin) is assessed for all patients in phase
1 of the study. During the vasoconstriction test, a bolus
of 2 μg/kg phenylephrine is administered intravenously,
after which the effect on SVR and MAP is registered.
The test is performed 5 times: t1) before induction; t2)
before induction, after start of cardiotropic drugs and/or
vasopressors (e.g. dobutamine, milrinone, norepineph-
rine) when necessary; t3) after induction; t4) 15 min after
cessation of cardiopulmonary bypass; and t5) on the first
postoperative day. The timepoints reflect different stages
perioperatively, during which the hemodynamic situ-
ation changes and that are present in all procedures that
are included in this study.
For the vasodilation test a bolus of 10 μg nitroglycerin
is given intravenously. The effect on SVR and MAP are
registered. Dosages are increased to 20 μg, 40 μg and
60 μg until a drop of 10% in MAP is reached. The vaso-
dilation test is performed twice: t1) before induction and
t5) 1 day post-operatively. The test is only performed at
these timepoints since we anticipate that in most heart
failure patients the test cannot be performed intraopera-
tively due to the hemodynamic effect. Before the test is
started, the patient needs to be in supine rest for at least
10 min.
Both the vasoconstriction and the vasodilation test will
only be performed when the clinical condition of the pa-
tient allows an increase or drop in MAP.
Ex vivo vascular reactivity tests
This test will be conducted in both phase 1 as phase 2 of the
study. A sample of pre-pericardial fat tissue, containing
resistance arteries, is collected before the cardiopulmonary
bypass is connected. The tissue is directly preserved in
Krebs-Henseleit buffer and transferred in a cooled box (±
4 °C) to the Erasmus Medical Center. Here, the tissue is
stored overnight at 4 °C. The next morning, the arterioles
are isolated, cut into ring segments of ±2mm length and
mounted in a Mulvany myograph. The 6ml organ baths
contain gassed Krebs-Henseleit buffer at 37 °C. The tension
on the segments is normalized to 90% of the estimated
diameter at 100mmHg of effective transmural pressure.
After a 30-min stabilization period, the maximal contractile
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response is determined by exposing the vessels to 30
and 100 mmol/L of potassium chloride. The following
concentration-response curves (CRCs) are constructed: 1)
phenylephrine (1 to 100 nmol/L); 2) vasopressin (0.1 to
300 nmol/L); 3) sodium nitroprusside (SNP) (1–100 μmol/
L); and 4) bradykinin (0.1 to 1000 nmol/L). bradykinin
CRCs are constructed in the absence or presence of
5) 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ)
(10 μmol/L, after concentration response curve 0.1 to
10 μmol/L) and 6) NG-nitro-L-arginine methyl ester
(L-NAME) (100 μmol/L, after CRC 1 to 100 μmol/L).
SNP and bradykinin induced relaxation was assessed
after preconstriction with U46619 (10 to 30 nmol/L,
aiming for 70–100% of the 100 mmol/L potassium
chloride contraction).
Another sample of fat tissue is fixed in 4% formalde-
hyde for 7 days and paraffin-embedded for later deter-
mination of activated signaling proteins (e.g. protein
kinase C, protein kinase G, protein kinase A) and the ex-
pression of receptors (e.g. β2, α1, V1a, AT1) using immu-
nohistochemistry. Furthermore, a small segment of
arterial tissue is snap-frozen in liquid nitrogen and
stored at − 80 °C for mRNA analysis. Precise analysis will
be guided by the findings of the functional tests.
Blood and urine sample
Arterial blood samples (one 10 ml ethylenediaminetetra-
acetic acid (EDTA) tube and one 8.5 ml serum-
separating tube) are collected at 5 time points during
phase 1 of the study: 1) before induction; 2) after induc-
tion; 3) after cardiopulmonary bypass; 4) on day 1 post-
operative and 5) on day 3 post-operative. The samples
are centrifuged at 1500 g, at 4 °C for 10 min. Plasma and
serum are stored in five 500 μl cups at − 80 °C to analyse
levels of organic compounds that can influence the car-
diovascular system (e.g. norepinephrine, epinephrine,
ANP, copeptin, NTproBNP, angiotensin II, cortisol,
aldosterone, renin, IL-1, IL-6 and TNF-α).
After an urinary catheter is placed, a urine sample is
collected. The sample is stored at − 80 °C until analysis
for levels of organic compound that effect the cardiovas-
cular system (e.g. steroids, VMA, angiotensinogen).
Precise analysis will be guided by the findings of the
functional tests.
Study parameters
The primary outcome is the change in SVR after phenyl-
ephrine administration at baseline.
The secondary outcomes are 1) change in MAP after
phenylephrine administration; 2) change in MAP and
SVR after nitroglycerin administration; 3) vasoplegia (de-
fined as the continuous need of vasopressors (norepin-
ephrine ≥0.2 μg/kg/min for at least 12 consecutive
hours, terlipressin or methylene blue) in combination
with a cardiac index ≥2,2 l/min/m2 for at least 12 con-
secutive hours, starting within the first 3 days post-
operatively); 4) Copeptin, norepinephrine, epinephrine,
ANP, BNP, NTproBNP, angiotensin II, cortisol, aldoster-
one, renin and VMA levels; 5) correlation between
change in SVR after phenylephrine administration and
clinical parameters (duration, amount and maximal con-
centration of norepinephrine postoperatively).
Ex vivo secondary outcomes are 1) change in vessel
diameter in response to vasoactive drugs; 2) activated
signaling proteins which are associated with vasorespon-
siveness; and 3) receptors (quantity and function) which
are associated with vasoresponsiveness.
Sample size calculation
The primary outcome is change in SVR after phenyleph-
rine administration at baseline. A sample size of 17 in
each group will have 90% power to detect a difference in
means of 400 dyn·s/cm5 assuming that the common
standard deviation is 350 dyn·s/cm5 [14] using a student
t-test with a 0.05 two-sided significance level. One extra
patient is included in each group to compensate for pos-
sible loss of data due to failing of the test, so 36 patients
are included in total in phase 1 of the study. In phase 2,
24 extra patients will be included.
Statistical analysis
All data of the in vivo and ex vivo tests are analyzed by a
researcher (respectively RW and RV) blinded for the
patient group. Baseline patient characteristics are de-
scribed using summary statistics. Continuous variables
are reported as mean with SD when normal distributed,
or as median with interquartile range when appropriate.
Differences between groups (heart failure versus no
heart failure) are compared using an unpaired Students
t-test, or Mann Whitney U-test. Categorical data is re-
ported as numbers and percentages. Fisher’s exact test is
used to compare the differences between groups. Pair-
wise deletion is used to handle missing data. The effect
of the vasoreactivity tests is adjusted for the level of used
vasoactive medication. The significance level is set at
P < 0.05. The Statistical Package for the Social Sciences
(SPSS, version 22) is used for the statistical analyses.
Consent
Participation in the study is voluntary and written in-
formed consent is obtained by the investigators (MV
and MP). Participants can withdraw their consent at any
time. Study findings will be disseminated through peer-
reviewed publications.
Data management
Handling of data complies with the Dutch Personal Data
Protection Act (in Dutch: De Wet Bescherming
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Persoonsgegevens, Wbp). A subject identification code
list is used to link data to the patient number of the pa-
tient and is stored on a secured computer on the study
site. The anonymous dataset is accessible for all investi-
gators of the research team.
Safety monitoring
A data monitoring committee deemed not to be neces-
sary since it concerns a non-randomized, non-blinded
study without serious safety concerns and no follow up.
All serious adverse events are reported to the medical
ethical committee within 7 days after the responsible in-
vestigator has first knowledge of the adverse event. All
protocol deviations and adverse events are recorded.
The investigators will submit a summary of the progress
to the medical ethical committee once a year, including
information on numbers of patients included, study pro-
gress, (serious) adverse events and amendments.
Discussion
The incidence and prevalence of chronic heart failure is
increasing. It is therefore to be expected that the number
of heart failure surgery procedures will increase. Unfortu-
nately, vasoplegia is frequently seen after these procedures
and is associated with a poor prognosis. The mechanism
that causes vasoplegia is thought to be multifactorial, but
the precise etiology remains unclear. This study is de-
signed to improve understanding of these mechanisms.
There are some issues in our study design that need to
be noted. First, since the vasoconstriction and the vaso-
dilation test can only be performed when the clinical
condition of the patient allows an increase or drop in
MAP, we expect that these tests cannot be conducted in
all patients. Secondly, baseline vasoreactivity tests are
performed uncalibrated since the central venous catheter
and the pulmonary artery catheter are introduced after
induction to limit the burden for the study patients.
Thirdly, collecting a sample of pre-pericardial fat tissue
can be difficult in patients who underwent previous car-
diac surgery. Furthermore, this tissue is fragile and it can
therefore be expected that we will not be able to per-
form the ex vivo vascular reactivity test in all included
patients.
Conclusion
In summary, this single-center prospective observational
study is designed to objectify and characterize the al-
tered vasoresponsiveness in patients with heart failure,
before, during and after heart failure surgery and to
identify the etiological factors involved. Understanding
the difference in vascular responsiveness between pa-
tients with and without heart failure in detail, might
yield therapeutic options or development of preventive
strategies for vasoplegia, leading to safer surgical inter-
ventions and improvement in outcome.
Trial status
The first patient was included on 10 February 2016. To
date, 36 patients are enrolled in the study. Recruitment
will be completed in 2019.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13019-019-1014-8.
Additional file 1. The Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) checklist.
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